First oral short-course treatment for relapsing- remitting multiple sclerosis (RRMS) now approved in Canada, which has one of the highest rates of MS in the world[1] Mavenclad has shown sustained clinical efficacy with a duration of oral treatment of 20... Biopharmaceuticals, Neurology, Regulatory Merck, Cladribine, MAVENCLAD, multiple sclerosis (Source: HSMN NewsFeed)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read full article on